Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07011654 · ClinicalTrials.gov registry record · Phase 1
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
A Phase 1 study of Metastatic Triple-Negative Breast Cancer, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT07011654 is a Phase 1 study of Metastatic Triple-Negative Breast Cancer that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 31 participants, below the 86-participant average among 5 other Metastatic Triple-Negative Breast Cancer trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07011654, a Phase 1 study of Metastatic Triple-Negative Breast Cancer, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I/II trial tests the safety, best dose, and effectiveness of naxitamab in combination with sacituzumab govitecan in treating patients with triple-negative breast cancer (TNBC) that has spread from where it first started (primary site) to other places in the body (metastatic).
Conditions Studied
Interventions
- DRUG Sacituzumab govitecan
- DRUG Naxitamab
Study Locations (1)
Texas
- The University of Texas M. D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2025-09-19 |
| Est. Completion | 2030-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07011654
The ClinicalTrials.gov registry entry for NCT07011654 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 86-participant average among 5 other Metastatic Triple-Negative Breast Cancer trials with a reported enrollment target (64% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Triple-Negative Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Sacituzumab govitecan is the first listed.
NCT07011654 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07011654 about?
NCT07011654 is a clinical study titled "Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)". This phase I/II trial tests the safety, best dose, and effectiveness of naxitamab in combination with sacituzumab govitecan in treating patients with triple-negative breast cancer (TNBC) that has spread from where it first started (primary site) to other places in the body (metastatic).
What is the current status of trial NCT07011654?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2025-09-19. Estimated completion is 2030-07-01.
What conditions does trial NCT07011654 study?
This clinical trial studies the following conditions: Metastatic Triple-Negative Breast Cancer.
What interventions are being tested in trial NCT07011654?
The interventions under investigation include: Sacituzumab govitecan (DRUG), Naxitamab (DRUG).
Who is sponsoring clinical trial NCT07011654?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07011654 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Triple-Negative Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Saci Nivo Rela for TNBC
RECRUITING · Phase 1
-
Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer
COMPLETED · Phase 1
-
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
RECRUITING · Phase 2
-
Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.